6 results
PrimaryThe primary objective of the study is to evaluate the rate of AF recurrences one month after randomization according to different timings of initiation of dronedaroSecondaryThe secondary efficacy objective is to evaluate the rate of AF…
Primary:To assess whether the addition of dronedarone (Multaq®) to existing conventional rate control therapy leads to a reduced ventricular rate after 1 week in patients with a high HR at rest during AF in comparison to an increase of conventional…
The primary objective of this trial is to demonstrate the efficacy of Dronedarone in preventing major cardiovascular events (stroke, systemic arterial embolism, myocardial infarction or cardiovascular death) or unplanned cardiovascular…
To demonstrate that dronedarone is superior to amiodarone in the maintenance of sinus rhythm after pharmacological, electrical or spontaneous conversion of AF.
Primary Objective is to test the feasibility of a strategy in which patient preference, after a short exposure to treatment options, determines the choice for a specific phosphate binder and whether this strategy will improve patient*s satisfaction.…
Primary Objective:- Determine the effect of 24 weeks of oral magnesium supplementation and/or the phosphate binder sucroferric oxyhydroxide on arterial wall stiffness in CKD patients, as measured by pulse wave velocity.Secondary Objectives:-…